Arrowhead Pharmaceuticals Inc. (ARWR): Among the NASDAQ Stocks With Biggest Upside Potential According to Analysts
Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) Have Lost 75%, as Stock Drops 13% This Past Week
Earnings Preview: ARWR to Report Financial Results Post-market on November 26
$Arrowhead Pharmaceuticals(ARWR.US)$ is scheduled to release its financial results post-market on November 26 ET. Earnings PreviewAnalysts estimate $Arrowhead Pharmaceuticals(ARWR.US)$ to post
Arrowhead Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Arrowhead Pharmaceuticals' Potential Approval of Clozasiran Drives Buy Rating and $60 Price Target
Piper Sandler Sticks to Its Buy Rating for Arrowhead Pharmaceuticals (ARWR)